VAV3 mediates resistance to breast cancer endocrine therapy-Reference-Cited by-同舟云学术

VAV3 mediates resistance to breast cancer endocrine therapy

Published:2014-05-28 Issue:3 Volume:16 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Aguilar Helena,Urruticoechea Ander,Halonen Pasi,Kiyotani Kazuma,Mushiroda Taisei,Barril Xavier,Serra-Musach Jordi,Islam Abul,Caizzi Livia,Di Croce Luciano,Nevedomskaya Ekaterina,Zwart Wilbert,Bostner Josefine,Karlsson Elin,Pérez Tenorio Gizeh,Fornander Tommy,Sgroi Dennis C,Garcia-Mata Rafael,Jansen Maurice PHM,García Nadia,Bonifaci Núria,Climent Fina,Soler María Teresa,Rodríguez-Vida Alejo,Gil Miguel,Brunet Joan,Martrat Griselda,Gómez-Baldó Laia,Extremera Ana I,Figueras Agnes,Balart Josep,Clarke Robert,Burnstein Kerry L,Carlson Kathryn E,Katzenellenbogen John A,Vizoso Miguel,Esteller Manel,Villanueva Alberto,Rodríguez-Peña Ana B,Bustelo Xosé R,Nakamura Yusuke,Zembutsu Hitoshi,Stål Olle,Beijersbergen Roderick L,Pujana Miguel Angel

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/bcr3664.pdf

Reference64 articles.

1. Musgrove EA, Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009, 9: 631-643.

2. Dowsett M, Dunbier AK: Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res. 2008, 14: 8019-8026.

3. Yue W, Fan P, Wang J, Li Y, Santen RJ: Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol. 2007, 106: 102-110.

4. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L, Gursky A, Siddiqui J, Tomlins SA, Roychowdhury S, Pienta KJ, Kim SY, Roberts JS, Rae JM, Van Poznak CH, Hayes DF, Chugh R, Kunju LP, Talpaz M, Schott AF, Chinnaiyan AM: Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013, 45: 1446-1451.

5. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, Harrison M, Mooney T, McMichael JF, Luo J, Tao Y, Goncalves R, Schlosberg C, Hiken JF, Saied L, Sanchez C, Giuntoli T, Bumb C, Cooper C, Kitchens RT, Lin A: Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013, 4: 1116-1130.

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hub metastatic gene signature and risk score of breast cancer patients with small tumor sizes using WGCNA;Breast Cancer;2024-08-27

2. Identification of differential biological activity and synergy between the PARP inhibitor rucaparib and its major metabolite;Cell Chemical Biology;2024-05

3. Key mRNAs and lncRNAs of pituitary that affect the reproduction of FecB + + small tail han sheep;BMC Genomics;2024-04-22

4. VAV3 in human cancers: Mechanism and clinical implication;Pathology - Research and Practice;2023-08

5. Risk stratification based on DNA damage-repair-related signature reflects the microenvironmental feature, metabolic status and therapeutic response of breast cancer;Frontiers in Immunology;2023-03-24